Takeda Wants End To Gout Drug Antitrust Case Midtrial

By P.J. D'Annunzio · September 19, 2023, 6:19 PM EDT

Takeda Pharmaceuticals is seeking an early end to an ongoing trial in an antitrust case brought by drug wholesalers over the delayed entry of a generic version of its gout drug...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Brief

Case Information

Case Title

VALUE DRUG COMPANY v. TAKEDA PHARMACEUTICALS, U.S.A., INC. et al

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Date Filed

August 05, 2021

Recent Articles By P.J.

November 06, 2024
Feds Fight Philly Injection Site Group's 3rd Circ. Appeal
October 15, 2024
LabCorp Gets Google Health Info Suit Sent To Arbitration
October 04, 2024
Prof. Claims Fox Chase, Temple U. Failed To Deter Harassment
October 01, 2024
NC Hospital Hit With More Class Claims Over Data Breach
August 28, 2024
Merck Must Face Class Claims In Vaccine Antitrust Suit
August 09, 2024
Pharmacy Escapes Recklessness Claim In Septic Shock Suit
August 06, 2024
Pennsylvania Hospital Gets Data Breach Suit Whittled
August 05, 2024
Insurer Must Face Pa. Trans Firefighter's Surgery Claim
July 31, 2024
CVS Appeal Blocked In Whistleblower Suit Over Drug Prices
July 19, 2024
Amazon Gets Tainted Eye Drop Suit Pared Down